- Report
- November 2020
- 241 Pages
Global
From €3060EUR$3,185USD£2,616GBP
€4372EUR$4,550USD£3,738GBP
- Report
- August 2020
- 65 Pages
United States
From €2018EUR$2,100USD£1,725GBP
€2883EUR$3,000USD£2,464GBP
- Report
- June 2020
- 133 Pages
Global
From €3060EUR$3,185USD£2,616GBP
€4372EUR$4,550USD£3,738GBP
- Report
- February 2022
- 149 Pages
Global
From €7206EUR$7,500USD£6,161GBP
- Drug Pipelines
- February 2022
- 74 Pages
Global
From €3795EUR$3,950USD£3,245GBP
- Report
- November 2021
- 120 Pages
Global
From €2402EUR$2,500USD£2,054GBP
- Report
- August 2022
United States
From €1864EUR$1,940USD£1,594GBP
- Report
- August 2022
Global
From €951EUR$990USD£813GBP
- Report
- February 2021
Global
From €2844EUR$2,960USD£2,432GBP
- Report
- February 2024
- 88 Pages
Global
From €3500EUR$3,902USD£3,097GBP
- Report
- February 2024
- 98 Pages
Global
From €3500EUR$3,902USD£3,097GBP
- Report
- May 2022
- 132 Pages
Global
From €2402EUR$2,500USD£2,054GBP
- Report
- March 2020
- 120 Pages
Global
From €4324EUR$4,500USD£3,697GBP
- Report
- January 2023
- 280 Pages
Global
From €5506EUR$5,730USD£4,707GBP
The Urinary Tract Infection Drug market is a subset of the Urological Disorders Drugs market. It is composed of drugs used to treat urinary tract infections (UTIs), which are caused by bacteria entering the urinary tract. These drugs are typically antibiotics, such as sulfonamides, cephalosporins, and fluoroquinolones. They are used to kill the bacteria and reduce the symptoms of the infection. Other drugs, such as antifungals, may also be used to treat UTIs.
The Urinary Tract Infection Drug market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, AstraZeneca, Sanofi, and Novartis. These companies are constantly developing new drugs to treat UTIs, as well as other urological disorders. Show Less Read more
